{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:17:51Z","timestamp":1770977871385,"version":"3.50.1"},"reference-count":95,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jaip.2017.08.031","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T02:46:05Z","timestamp":1509936365000},"page":"1477-1487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines"],"prefix":"10.1016","volume":"5","author":[{"given":"Mark","family":"Boguniewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2017.08.031_bib1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jaci.2014.12.1907","article-title":"Targeted therapy for allergic diseases: at the intersection of cutting-edge science and clinical practice","volume":"135","author":"Boguniewicz","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2010.251","article-title":"Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health","volume":"131","author":"Shaw","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib4","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib5","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/jamadermatol.2016.5538","article-title":"Global skin disease morbidity and mortality: an update from the Global Burden of Disease Study 2013","volume":"153","author":"Karimkhani","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jamadermatol.2013.10271","article-title":"Persistence of mild to moderate atopic dermatitis","volume":"150","author":"Margolis","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib8","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","article-title":"Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go?","volume":"139","author":"Bieber","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaci.2009.10.055","article-title":"Infant-onset eczema in relation to mental health problems at age 10 years: results from a prospective birth cohort study (German Infant Nutrition Intervention plus)","volume":"125","author":"Schmitt","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1067\/mjd.2002.120528","article-title":"Cost of atopic dermatitis and eczema in the United States","volume":"46","author":"Ellis","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jid.2017.02.975","article-title":"Inpatient financial burden of atopic dermatitis in the United States","volume":"137","author":"Narla","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-065X.2011.01027.x","article-title":"Atopic dermatitis: a disease of altered skin barrier and immune dysregulation","volume":"242","author":"Boguniewicz","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaip.2017.08.031_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fimmu.2015.00353","article-title":"Regulation of T cell immunity in atopic dermatitis by microbes: the Yin and Yang of cutaneous inflammation","volume":"6","author":"Biedermann","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2015.07.007","article-title":"Barrier epithelial cells and the control of type 2 immunity","volume":"43","author":"Hammad","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2017.08.031_bib17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","article-title":"Increasing comorbidities suggest that atopic dermatitis is a systemic disorder","volume":"137","author":"Brunner","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2016.02.045","article-title":"Resolving the etiology of atopic disorders by using genetic analysis of racial ancestry","volume":"138","author":"Gupta","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib21","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jaci.2016.10.004","article-title":"Advances in atopic dermatitis in 2015","volume":"138","author":"Nomura","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaip.2017.08.031_bib23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI117408","article-title":"Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis","volume":"94","author":"Hamid","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2017.08.031_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0091-6749(96)70246-4","article-title":"In\u00a0vivo expression of IL-12 and IL-13 in atopic dermatitis","volume":"98","author":"Hamid","year":"1996","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/pde.12867","article-title":"Study of the atopic march: development of atopic comorbidities","volume":"33","author":"Schneider","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib27","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/all.12685","article-title":"Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies","volume":"70","author":"Silverberg","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.08.031_bib28","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaci.2014.11.023","article-title":"Eczema and cardiovascular risk factors in 2 US adult population studies","volume":"135","author":"Silverberg","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib29","doi-asserted-by":"crossref","unstructured":"Kwa MC, Silverberg JI. Association between inflammatory skin disease and cardiovascular and cerebrovascular co-morbidities in US adults: analysis of nationwide inpatient sample data [published online ahead of print May 22, 2017]. Am J Clin Dermatol. http:\/\/dx.doi.org\/10.1007\/s40257-017-0293-x.","DOI":"10.1007\/s40257-017-0293-x"},{"key":"10.1016\/j.jaip.2017.08.031_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaci.2015.06.029","article-title":"Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes","volume":"137","author":"Schmitt","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/all.12246","article-title":"Nonallergic comorbidities of atopic eczema: an overview of systematic reviews","volume":"69","author":"Deckert","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.08.031_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjd.14708","article-title":"Association between atopic dermatitis and extracutaneous infections in US adults","volume":"176","author":"Strom","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12920-015-0133-x","article-title":"Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways","volume":"8","author":"Ewald","year":"2015","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jaip.2017.08.031_bib34","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/all.12982","article-title":"Atopic dermatitis, atopic eczema, or eczema? A systematic review, meta-analysis, and recommendation for uniform use of \u2018atopic dermatitis\u2019","volume":"71","author":"Kantor","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.08.031_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.iac.2016.08.008","article-title":"Current and future biomarkers in atopic dermatitis","volume":"37","author":"Thijs","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2017.08.031_bib36","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jaci.2016.04.018","article-title":"A\u00a0computational model to predict severity of atopic eczema from 30 serum proteins","volume":"138","author":"Krause","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib37","doi-asserted-by":"crossref","first-page":"e17520","DOI":"10.1371\/journal.pone.0017520","article-title":"Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010","volume":"6","author":"Rehal","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2017.08.031_bib38","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jaci.2013.07.008","article-title":"Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation","volume":"132","author":"Schmitt","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib39","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaci.2014.07.043","article-title":"The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials","volume":"134","author":"Schmitt","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","article-title":"EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference","volume":"67","author":"Schram","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.08.031_bib41","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/bjd.13662","article-title":"What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study","volume":"172","author":"Leshem","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A\u00a0systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards","volume":"74","author":"Futamura","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib43","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jaci.2017.01.009","article-title":"Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines","volume":"139","author":"Eichenfield","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaci.2012.12.672","article-title":"Atopic dermatitis: a practice parameter update 2012","volume":"131","author":"Schneider","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2133.2010.10030.x","article-title":"Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials","volume":"164","author":"Schmitt","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib46","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaad.2014.08.038","article-title":"Guidelines of care for the management of atopic dermatitis, section 4: prevention of disease flares and use of adjunctive therapies and approaches","volume":"71","author":"Sidbury","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis, section 3: management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib48","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1172\/JCI116240","article-title":"Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens","volume":"91","author":"Takei","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2017.08.031_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0190-9622(99)70544-X","article-title":"Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis","volume":"40","author":"Jolles","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib50","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib51","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0002-9343(90)90490-5","article-title":"Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels","volume":"88","author":"Boguniewicz","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2017.08.031_bib52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0190-9622(93)70026-P","article-title":"Recombinant interferon gamma therapy for atopic dermatitis","volume":"28","author":"Hanifin","year":"1993","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib53","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1081-1206(10)62968-7","article-title":"Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis","volume":"80","author":"Schneider","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib54","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/archderm.134.7.799","article-title":"Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels","volume":"134","author":"Stevens","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib55","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archderm.134.7.870","article-title":"Atopic dermatitis: a question of balance","volume":"134","author":"Boguniewicz","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1525-1470.2010.01356.x","article-title":"The clinical spectrum and therapeutic challenge of eczema herpeticum","volume":"28","author":"Frisch","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib57","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0091-6749(97)70031-9","article-title":"Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration","volume":"99","author":"Cheng","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib58","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.08.031_bib59","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000095299","article-title":"No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients","volume":"141","author":"Oldhoff","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib60","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaad.2013.05.035","article-title":"Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective","volume":"69","author":"Lacombe Barrios","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib61","first-page":"990","article-title":"Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study","volume":"8","author":"Heil","year":"2010","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaip.2017.08.031_bib62","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jaci.2007.08.060","article-title":"Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels","volume":"120","author":"Belloni","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib63","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/all.12234","article-title":"Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines","volume":"69","author":"Hotze","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.08.031_bib64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","article-title":"Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial","volume":"162","author":"Iyengar","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib65","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jaci.2016.05.038","article-title":"Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis","volume":"138","author":"Wang","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib66","first-page":"190","article-title":"Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis","volume":"23","author":"S\u00e1nchez-Ram\u00f3n","year":"2013","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib67","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaci.2007.11.016","article-title":"Anti-CD20 (rituximab) treatment improves atopic eczema","volume":"121","author":"Simon","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib68","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jaci.2008.03.007","article-title":"Anti-CD20 (rituximab) treatment for atopic eczema","volume":"121","author":"Sediv\u00e1","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib69","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/sj.jid.5701169","article-title":"Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen","volume":"128","author":"Harper","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib70","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archderm.142.5.555","article-title":"Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab","volume":"142","author":"Weinberg","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib71","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archderm.143.8.1077","article-title":"Long-term follow-up of a child treated with efalizumab for atopic dermatitis","volume":"143","author":"Siegfried","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib72","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaad.2006.08.031","article-title":"Efalizumab for severe atopic dermatitis: a pilot study in adults","volume":"56","author":"Takiguchi","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib73","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1468-3083.2009.03202.x","article-title":"Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases","volume":"24","author":"Ibler","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2017.08.031_bib74","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/imt.15.69","article-title":"Drug evaluation review: dupilumab in atopic dermatitis","volume":"7","author":"Hamilton","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaip.2017.08.031_bib75","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.08.031_bib76","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib77","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2017.08.031_bib78","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.08.031_bib79","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.08.031_bib80","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent\u00a0asthma despite use of medium-to-high-dose inhaled corticosteroids plus\u00a0a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2017.08.031_bib81","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2017.08.031_bib82","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2017.08.031_bib83","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaci.2005.10.046","article-title":"IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis","volume":"117","author":"Bilsborough","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib84","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jdermsci.2014.02.009","article-title":"Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis","volume":"74","author":"Kato","year":"2014","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2017.08.031_bib85","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib86","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.08.031_bib87","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2017.08.031_bib88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2016.07.047","article-title":"Ustekinumab treatment in severe atopic dermatitis: down-regulation of T-helper 2\/22 expression","volume":"76","author":"Weiss","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib89","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5021\/ad.2013.25.3.368","article-title":"Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab","volume":"25","author":"Agusti-Mejias","year":"2013","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib90","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jdv.12918","article-title":"Inadequate response to ustekinumab in atopic dermatitis\u2014a report of two patients","volume":"30","author":"Samorano","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2017.08.031_bib91","doi-asserted-by":"crossref","unstructured":"Nic Dhonncha E, Clowry J, Dunphy M, Buckley C, Field S, Paul L. Treatment of severe atopic dermatitis with ustekinumab: a case series of 10 patients [published online ahead of print December 22, 2016]. Br J Dermatol. http:\/\/dx.doi.org\/10.1111\/bjd.15262.","DOI":"10.1111\/bjd.15262"},{"key":"10.1016\/j.jaip.2017.08.031_bib92","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.15493","article-title":"Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomised, double-blind, placebo-controlled, phase II Study","volume":"177","author":"Saeki","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib93","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"26","author":"Khattri","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaip.2017.08.031_bib94","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.031_bib95","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13R\u03b11 and IL-13R\u03b12","volume":"429","author":"Popovic","year":"2017","journal-title":"J\u00a0Mol Biol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219817307158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219817307158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:15:42Z","timestamp":1761974142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219817307158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":95,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S2213219817307158"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2017.08.031","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2017.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}